Immunomodulator, B-Lymphocyte Stimulator (BLyS)-Spec Inhib

The therapeutic class "Immunomodulator, B-Lymphocyte Stimulator (BLyS)-Specific Inhibitor" consists of targeted biologic therapies, primarily exemplified by the monoclonal antibody belimumab The primary therapeutic application is the management of autoimmune disorders, most notably active systemic lupus erythematosus and active lupus nephritis

The therapeutic class "Immunomodulator, B-Lymphocyte Stimulator (BLyS)-Specific Inhibitor" consists of targeted biologic therapies, primarily exemplified by the monoclonal antibody belimumab

These agents work by selectively binding to and neutralizing soluble B-lymphocyte stimulator cytokine, preventing it from interacting with its receptors on B cells This inhibition suppresses autoreactive B-cell survival and reduces the differentiation of B cells into autoantibody-producing plasma cells

These agents work by selectively binding to and neutralizing soluble B-lymphocyte stimulator cytokine, preventing it from interacting with its receptors on B cells This inhibition suppresses autoreactive B-cell survival and reduces the differentiation of B cells into autoantibody-producing plasma cells

The primary therapeutic application is the management of autoimmune disorders, most notably active systemic lupus erythematosus and active lupus nephritis